PURPOSE: For nanocarrier-based targeted delivery systems, preventing phagocytosis for prolong circulation half life is a crucial task. PEGylated poly(n-butylcyano acrylate) (PBCA) NP has proven a promising approach for drug delivery, but an easy and reliable method of PEGylation of PBCA has faced a major bottleneck. METHODS: PEGylated PBCA NPs containing docetaxel (DTX) by modified anionic polymerization reaction in aqueous acidic media containing amine functional PEG were made as an single step PEGylation method. In vitro colloidal stability studies using salt aggregation method and antiopsonization property of prepared NPs using mouse macrophage cell line RAW264 were performed. In vitro performance of anticancer activity of prepared formulations was checked on MCF7 cell line. NPs were radiolabeled with 99mTc and intravenously administered to study blood clearance and biodistribution in mice model. RESULTS: These formulations very effectively prevented phagocytosis and found excellent carrier for drug delivery purpose. In vivo studies display long circulation half life of PBCA-PEG20 NP in comparison to other formulations tested. CONCLUSIONS: The PEGylated PBCA formulation can work as a novel tool for drug delivery which can prevent RES uptake and prolong circulation half life.
PURPOSE: For nanocarrier-based targeted delivery systems, preventing phagocytosis for prolong circulation half life is a crucial task. PEGylated poly(n-butylcyano acrylate) (PBCA) NP has proven a promising approach for drug delivery, but an easy and reliable method of PEGylation of PBCA has faced a major bottleneck. METHODS: PEGylated PBCA NPs containing docetaxel (DTX) by modified anionic polymerization reaction in aqueous acidic media containing amine functional PEG were made as an single step PEGylation method. In vitro colloidal stability studies using salt aggregation method and antiopsonization property of prepared NPs using mouse macrophage cell line RAW264 were performed. In vitro performance of anticancer activity of prepared formulations was checked on MCF7 cell line. NPs were radiolabeled with 99mTc and intravenously administered to study blood clearance and biodistribution in mice model. RESULTS: These formulations very effectively prevented phagocytosis and found excellent carrier for drug delivery purpose. In vivo studies display long circulation half life of PBCA-PEG20 NP in comparison to other formulations tested. CONCLUSIONS: The PEGylated PBCA formulation can work as a novel tool for drug delivery which can prevent RES uptake and prolong circulation half life.
Authors: M Müller; J Vörös; G Csúcs; E Walter; G Danuser; H P Merkle; N D Spencer; M Textor Journal: J Biomed Mater Res A Date: 2003-07-01 Impact factor: 4.396
Authors: Michael E Werner; Jonathan A Copp; Shrirang Karve; Natalie D Cummings; Rohit Sukumar; Chenxi Li; Mary E Napier; Ronald C Chen; Adrienne D Cox; Andrew Z Wang Journal: ACS Nano Date: 2011-10-28 Impact factor: 15.881
Authors: Derek Reichel; Louis T Curtis; Elizabeth Ehlman; B Mark Evers; Piotr Rychahou; Hermann B Frieboes; Younsoo Bae Journal: Pharm Res Date: 2017-08-24 Impact factor: 4.200
Authors: Mallory R Gordon; Bo Zhao; Francesca Anson; Ann Fernandez; Khushboo Singh; Celia Homyak; Mine Canakci; Richard W Vachet; S Thayumanavan Journal: Biomacromolecules Date: 2018-02-08 Impact factor: 6.988
Authors: Hongmei Li; Shann S Yu; Martina Miteva; Christopher E Nelson; Thomas Werfel; Todd D Giorgio; Craig L Duvall Journal: Adv Funct Mater Date: 2013-06-25 Impact factor: 18.808